BIO Stalwart Greenwood Announces Departure
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
You may also be interested in...
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.